Background
Microglial cells are a major retinal glial constituent derived from the mononuclear phagocyte lineage, and play a crucial role as the principle resident immunocompetent and phagocytic cells of the central nervous system (CNS), including the retina. Through persistent surveillance of their microenvironment, microglia act as motile sensors that help maintain homeostasis in retina through a variety of functions, including facilitating phagocytosis of debris and apoptotic cells [
1‐
3], antigen presentation [
4‐
7], and secretion of neuroprotective factors [
8,
9].
Recruitment of microglia/monocytes to damaged regions occurs in almost every pathological condition in the CNS [
10,
11], and is apparent in a range of prominent human retinal pathologies including age-related macular degeneration (AMD) [
2,
12‐
15], retinitis pigmentosa [
2], late-onset retinal degeneration [
2], retinal detachment [
16], glaucoma [
17‐
19], and diabetic retinopathy [
17,
20], as well as in many experimental models of retinal degeneration [
9]. Despite their beneficial properties, widespread recruitment and activation of microglia may damage neurons [
21‐
25], probably through their secretion of pro-inflammatory mediators and cytotoxic factors, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β [
10,
26,
27], and nitric oxide [
23,
28,
29]. Moreover, microglial activation is directly implicated in models of neovascular AMD [
30], light-induced damage [
21,
31‐
33], diabetic retinopathy [
34,
35], glaucoma [
36,
37], chronic photoreceptor degeneration in
rds (retinal degeneration slow) mice [
38], and photoreceptor apoptosis
in vitro[
22].
In spite of their prominent role in retinal degeneration, the precise signaling events that mediate the trafficking of microglia/monocytes in the retina are not yet elucidated [
39]. Chemokines are a large family of molecules that have potent chemoattractant properties in the recruitment of leukocytes in immune surveillance and inflammation in the CNS [
40‐
43]. Chemokine expression results in the establishment of chemical ligand gradients that serve as directional cues for the guidance of certain leukocytes to sites of injury [
40]. Chemokine (C-C motif) ligand (Ccl)2 is one of the most well-characterized chemokines [
44], and is a potent chemoattractant and activator for monocytes and microglia
in vitro[
45‐
47]. Upregulation of Ccl2 is also implicated in a number of CNS pathologies such as Alzheimer’s disease [
48,
49], multiple sclerosis [
50,
51], frontotemporal lobe dementia [
52], and brain trauma [
53,
54]. We have shown previously that the expression of Ccl2 is upregulated in Müller cells in a light-induced model of retinal degeneration [
55], which coincides spatiotemporally with the local recruitment of microglia/monocytes and the region of peak photoreceptor death [
56].
In the current study, we aimed to investigate the role of Müller-cell-derived Ccl2 in the recruitment of retinal monocytes/microglia following exposure to bright continuous light (BCL), using targeted small interfering (si)RNA to suppress Ccl2 expression in the retina. siRNA molecules are short sequences of double-stranded RNA, which serve as a component of RNA interference (RNAi) [
57]. The RNAi cellular machinery enables the specific degradation of a target mRNA of complementary sequence, which effectively silences expression of the particular gene [
58]. In this study, we found that intravitreal administration of Ccl2 siRNA suppressed expression of Ccl2 by Müller cells, resulting in an inhibition of microglia/monocyte recruitment and reduction in photoreceptor death following BCL exposure. Consequently, inhibition of endogenous chemokine expression using siRNA may present a viable means to modulate excessive microglial activation in the degenerating retina.
Methods
Ethics approval
The study was approved by the Animal Experimentation Ethics Committee (AEEC) of the Australian National University (R.BSB.05.10). All experiments conducted were in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.
Animals
Adult Sprague–Dawley (SD) rats aged between postnatal days 160 and 190 were used for the experiments. The rats were born and reared in dim cyclic light conditions with an ambient level of approximately 5 lux, until the commencement of bright-light exposure.
Preparation of small interfering RNA and intravitreal injection
RNAi was achieved using a cocktail of two commercially available modified siRNAs, specific for Ccl2 (Stealth siRNA; #RSS302703 and #RSS302704; Invitrogen Inc., Carlsbad, CA USA). A scrambled siRNA equivalent, not homologous to any known gene, served as a negative control, and was conjugated to an Alexa 555 fluorophore to assess the uptake of siRNA in the retina (#14750–100; Invitrogen Inc.). Before administration, siRNAs were encapsulated using a cationic liposome-based formulation (Invivofectamine; #1377–901; Invitrogen Inc.) in accordance with the manufacturer’s instructions. The final concentration of each encapsulated siRNA formulation was 0.33 μg/μl in a 5% glucose solution.
For intravitreal injections, animals were anaesthetized with an intraperitoneal injection containing 30 mg ketamine (100 mg/ml; Troy Laboratories, NSW, Australia) and 3 mg xylazil (20 mg/ml; Parnell, NSW, Australia). A drop of 1% atropine (Chauvin Pharmaceuticals, London, England) was applied to the ocular surface to produce mydriasis, and the injection site was then swabbed with 5% povidone iodine (Betadine; Faulding Pharmaceuticals, SA, Australia). Intravitreal injection was then performed as described previously [
59]; 3 μL of either positive or negative siRNA complex, corresponding to 1 μg of siRNA, was injected into both eyes of each animal. For an additional control, 3 μLof transfection agent only was also injected into both eyes of some animals. After injection, neomycin ointment 5 mg/g (Amacin; Jurox, NSW, Australia) was applied to the injection site to prevent infection.
Light exposure
After intravitreal injections, the animals were immediately transferred to individual cages designed to allow light to enter unimpeded. BCL exposure was achieved using an 18 W fluorescent light source (Cool White; TFC, Taipei, Taiwan) positioned above the cages, , which was run from 11.00 to 24.00 hours, and kept at an intensity of approximately 1000 lux at the cage floor. Corneal hydration was maintained by application of a synthetic tear gel (GenTeal Gel; Novartis, NSW, Australia) during BCL, until the animals awoke. Animals were exposed to BCL for 24 hours before tissue collection.
Tissue collection and processing
Animals were killed using an overdose (60 mg/kg bodyweight) of barbiturate (Valabarb; Virbac, Australia) given as intraperitoneal injection, then retinal tissue was obtained from each treatment group for analysis. Eyes from some animals were marked at the superior surface for orientation, then enucleated and processed for sectioning on a cryostat, while the retina from others was excised through a corneal incision and prepared for RNA extraction.
Eyes for sectioning were immediately immersion-fixed in 4% paraformaldehyde in 0.1 M PBS (pH 7.3) for 3 hours at room temperature, then processed as previously described [
56], and sectioned at 16 μm on a cryostat. Retinas for RNA extraction were immediately immersed in chilled solution (RNAlater; #7024; Ambion Inc., Austin, TX, USA), then stored in accordance with the manufacturer’s instructions. The RNA was then extracted from each sample and analyzed as previously described [
55,
60].
Quantitative real-time PCR
First-strand cDNA synthesis was performed as described previously [
55]. Gene amplification was measured using commercially available hydrolysis probes (TaqMan®; Applied Biosystems, Foster City, CA, USA) (Table
1). The hydrolysis probes were used in accordance with a previously described quantitative (q)PCR protocol [
55]. The fold change was analyzed using the
ΔΔC
q method, with expression of the target gene normalized relative to the expression of two reference genes: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and β-actin. Amplification specificity was assessed using gel electrophoresis.
Table 1
Taqman probes used
β-actin | Beta-actin | Rn00667869_m1 | NM_031144.2 |
Ccl2 | Chemokine (C-C motif) ligand 2 | Rn01456716_g1 | NM_031530.1 |
GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Rn99999916_s1 | NM_017008.3 |
Jun (AP-1) | Jun oncogene (transcription factor activator protein −1) | Rn99999045_s1 | NM_021835.3 |
In situ hybridization
To investigate localization of Ccl2 mRNA transcripts in the retina following RNAi, a riboprobe to Ccl2 was generated for
in situ hybridization on frozen sections of retinal tissue. Synthesis of the Ccl2 riboprobe and
in situ hybridization were performed as described previously [
55,
61]. The Ccl2 riboprobe was hybridized overnight at 55°C, and then washed in saline sodium citrate (pH 7.4) at 60°C. After hybridization, some sections were further stained using immunohistochemistry (see below).
Analysis of cell death
Following BCL, terminal dUTP nick end labeling (TUNEL) was used to quantify photoreceptor apoptosis in cryostat sections for each treatment group, using a previously published protocol [
62]. Counts of TUNEL-positive cells in the outer nuclear layer (ONL) were carried out along the full length of retinal sections cut in the parasagittal plane (superio-inferior), within the vertical meridian. The total count from each retina is the average of four sections at comparable locations.
Immunohistochemistry
Frozen sections from each treatment group were used for immunohistochemical analysis, using the primary antibodies listed in Table
2. Immunohistochemistry was performed as previously described [
55]. Immunofluorescence was viewed using a laser scanning microscope (Carl Zeiss, Jena, Germany), and acquired using PASCAL software (version 4.0; Carl Zeiss). Images were prepared for publication using Adobe Photoshop software.
Table 2
Antibodies used for immunohistochemistry
Hamster α-Ccl2 | 1:100 | 505902 | Biolegend, San Diego, CA, USA |
Mouse α-ED1 | 1:200 | MAB1435 | Invitrogen Inc., Carlsbad, CA, USA |
Rabbit α-IBA1 | 1:400 | 019–19741 | Wako, Osaka, Japan |
Mouse α-S100β | 1:200 | S2532 | Sigma Chemical Co., St. Louis, MO, USA |
Mouse α-vimentin | 1:200 | 18-0052 | Zymed, San Francisco, CA, USA |
Quantification of monocytes/microglia
Monocyte/microglia counts were performed on sections immunolabeled jointly with the markers ED1 and ionized calcium binding adaptor (IBA)1. Numbers of ED1+/IBA + and ED1−/IBA1+ nuclei were assessed long the full length of retinal sections cut in the parasagittal plane (supero-inferior) within the vertical meridian. Counts were made of all ED1+/IBA + monocytes throughout the retina, including the retinal vasculature, ONL, and choroidal vasculature. Counts of /ED1−/IBA1+ parenchymal microglia encompassed those in the outer plexiform layer (OPL) and ONL/subretinal space (but not the resting population in the inner plexiform layer; IPL), as microglia recruit to these areas when activated during retinal degeneration [
9,
47,
63]. The total counts of ED1+/IBA + and ED1−/IBA1+ nuclei from each retina was the average of four sections at comparable locations.
Quantification of chemokine (C-C motif) ligand (Ccl)2-expressing Müller cells
Ccl2 expression following RNAi in Müller cells was assessed on frozen sections after either immunohistochemistry or in situ hybridization for Ccl2 (as described above). In Ccl2-immunolabeled sections, the number of Ccl2-immunoreactive Müller cell processes was assessed. In sections used for in situ hybridization, counts were made of Ccl2-expressing Müller cell bodies. Both sets of counts were conducted across the full length of retinal sections cut in the parasagittal plane (supero-inferior) within the vertical meridian; the total count was the average of four sections at comparable locations.
Statistical analysis
Statistical analysis for each experiment was performed using one-way ANOVA with Tukey’s multiple comparison post hoc test. For each analysis, P < 0.05 was considered significant.
Discussion
The findings of the current study confirm a key role for Müller cells and Ccl2 in the retinal neuroinflammatory response in the light-damage model of retinal degeneration. Firstly, using both in situ hybridization and immunohistochemistry, we confirmed the efficacy of siRNA transfection in targeted suppression of Ccl2 expression in Müller glia following damage. Second, we found that suppression of Ccl2 mRNA in Müller cells inhibited the recruitment of both ED1-positive and IBA1-positive monocytes/microglia to the injured retina after BCL exposure. Third, our data showed that photoreceptor death was reduced after BCL when Ccl2 expression was inhibited by Ccl2 siRNA.
Previous investigators have theorized that Müller cells or retinal pigment epithelial cells (RPE) may be the source of chemokines that mediate neuroinflammation following light-induced degeneration [
67],and several studies have shown that RPE cells
in vitro express Ccl2 in response to stimulatory cytokines in the extracellular environment [
68‐
72]. The present study is the first, to our knowledge, to directly confirm that Müller cells guide monocyte/microglia recruitment in the retina through the expression of Ccl2 mRNA, and that such expression exacerbates photoreceptor death following the initial damaging-light stimulus. This is consistent with our previous investigation, which found that Müller cells express Ccl2 in spatiotemporal correlation with the recruitment of ED1-positive monocytes and photoreceptor death following BCL exposure [
55].
Our data point to a crucial role for chemokines in the propagation of local neuroinflammatory responses driven by the neural retina. Ccl2 is a strong chemoattractant and activator of monocytes [
46] and microglia [
47]
in vitro, and is induced in the CNS in a range of pathologies (reviewed in [
42]). Our data indicate that Ccl2 upregulation by Müller cells promotes the recruitment of two monocyte/microglia populations immunoreactive for the markers ED1 and IBA1 in the retina following BCL exposure [
65]. First are parenchymal microglia immunoreactive for IBA1, which infiltrate the OPL and ONL after BCL [
63,
65]. Second, there is modulation of ED1+/IBA1+ nuclei recruited from the retinal and choroidal blood supplies, which is consistent with the markers, morphology, and distribution of bone-marrow-derived ‘hematogenus’ monocytes [
65,
66,
73]. These findings are supported by a previous study in the CNS using Ccr2-knockout mice subjected to partial sciatic nerve ligation, which showed that the Ccr2 chemokine receptor, of which Ccl2 is a known ligand [
74], mediates the recruitment of both hematogenous and resident microglia/monocytes immunoreactive for IBA1 [
75].
Because both bone-marrow and resident microglia/monocytes are implicated in the clearance of debris and dead photoreceptors after injury [
66], the expression of Ccl2 by Müller cells may promote homeostasis and recovery through efficient recruitment and activation of phagocytes to sites of photoreceptor degeneration. However, given that we found a decrease in photoreceptor apoptosis and expression of AP-1 following suppression of Ccl2 by siRNA, the secretion of Ccl2 by Müller cells may be a maladapted process, which is prone to eliciting exaggerated and damaging microglial responses. A number of studies have shown that microglial activation and aggregation exacerbates photoreceptor degeneration in the light-damage model [
32,
33], whereas activated microglia induce apoptosis of cultured photoreceptors through the secretion of cytotoxic factors
in vitro[
22]. Moreover, the introduction of synthetic Ccl2 to cultured microglial cells or monocytes has been shown to promote their activation and cytotoxicity toward co-cultured photoreceptors and RPE cells [
47,
76]. The signaling events that govern the synthesis of Ccl2 by Müller cells are unknown, although upregulation of Ccl2 may be stimulated as a result of local photoreceptor death, because increased levels of Ccl2 in Müller cells correlates spatially with the localization of light-induced photoreceptor apoptosis, as shown in our previous investigation [
55]. Alternatively, or perhaps concurrently, Ccl2 synthesis may be stimulated by the presence of cytokines in the extracellular environment, such as IL-1β, IL-7, and TNF-α [
68,
71,
77], following BCL exposure.
Our findings are consistent with other studies that have characterized Ccl2 as a non-redundant factor in the guidance of microglia/monocytes in a variety of degenerative models. In the retina, an investigation in experimental retinal detachment using Ccl2
−/
− mice and Ccl2-specific antibody neutralization noted a substantial decrease in the recruitment of parenchymal microglia to the ONL following detachment, in conjunction with reduced photoreceptor death [
47]. Deficiencies in monocyte recruitment have also been reported after Ccl2 inhibition in other models such as skin inflammation [
78], thioglycollate challenge [
79], experimental autoimmune encephalomyelitis [
80], pulmonary granuloma [
79], and peripheral endotoxin insult [
81]. Despite this, a previous investigation did not observe modulation in a population of F4/80-positive macrophages in the subretinal space following light-induced damage to Ccl2
−/
− mice [
82]. As discussed in our previous investigation, however [
55], the authors in that investigation did not quantify those cells, nor did they assess the distribution of other microglial markers such as ED1 and IBA1.
Relevance to human retinal dystrophies
Exposure to bright continuous light in rats has been used to model retinal degeneration for over 40 years [
83,
84]. Several lines of evidence also indicate that light damage is a useful model of AMD [
56,
85‐
87]. This model, like the established laser-induced model of neovascular AMD, uses an acute damaging stimulus to evoke site-specific AMD-like retinal degeneration. Although the rat retina lacks a macula and
fovea centralis, it includes an homologous feature, the
area centralis, in superiotemporal retina [
88‐
90]. Previous studies have identified the focal degeneration of photoreceptors and RPE cells and associated changes to the blood–retinal barrier as being localized to the
area centralis, thus mimicking many of the histopathological aspects of advanced ‘dry’ AMD [
56,
85‐
87].
Recruitment of monocytes/microglia has been associated with the progression and severity of AMD pathology for many years [
2,
12‐
15], while several investigations have shown that microglial attenuation reduces lesion size in the laser-induced model of neovascular ‘wet’ AMD [
91‐
93]. Retinas from human donors show increased expression for Ccl2 in all forms of AMD [
94], while increased levels of Ccl2 protein have been detected in aqueous humor samples taken from patients in advanced stages of ‘wet’ and ‘dry’ AMD [
95,
96]. Increased
Cc2 expression has also been described in the retinas of aged (20-month-old) mice, compared with young (3-month-old) mice [
97]. Moreover, studies in experimental laser-induced choroidal neovascularization (CNV) have shown that ablation of either
Ccl2 or the receptor
Ccr2 inhibits the infiltration of monocytes/microglia and reduces lesion size following CNV [
98,
99]. Conversely, it has been previously suggested that aging Ccl2
−/
− Ccr2
−/
− mice develop AMD-like retinal degeneration [
100,
101], indicating that a degree of Ccl2 signaling is also required for homeostasis, although the AMD-like phenotype in the knockout has been questioned [
98].
siRNA-mediated gene therapy is considered to have therapeutic potential in knocking down deleterious genes in various human pathologies (reviewed in [
102,
103]). Our investigation is the first to show that monocyte recruitment, and in turn photoreceptor death, may be modified in the retina by siRNA-mediated suppression of Ccl2
in vivo in the CNS. Previous studies in AMD have shown that intravitreally injected siRNA targeting vascular endothelia growth factor ameliorates retinal degeneration in experimental CNV [
104,
105], and has also been the basis for several clinical trials [
106]. However, unlike the current investigation, these early studies used ‘naked’ unmodified siRNA molecules, which are now known to produce non-specific effects via Toll-like receptor 3 signaling in the retina [
106]. Nevertheless, modulation of Ccl2 expression using appropriately targeted RNAi may provide a powerful means to control excessive microglial recruitment and activation in retinal dystrophies such as AMD.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MVR designed and conducted the experiments, conducted the analysis, and wrote the paper; RCN designed and conducted the experiments; and JMP designed the experiments, and wrote the paper. All authors read and approved the final manuscript.